STOCK TITAN

[Form 4] ARGAN INC Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Charles E. Collins IV, CEO of Argan, Inc. (AGX), reported option exercise and subsequent open-market sale on 09/18/2025. He exercised 7,500 shares of a stock option granted 09/12/2018 at an exercise price of $43.10 per share, and immediately sold 7,500 shares on the open market at $257.39 per share. Following these transactions the filing shows 21,006 shares beneficially owned directly and 44,735 shares underlying options/derivatives reported as beneficially owned. The Form 4 is signed and dated 09/22/2025.

Charles E. Collins IV, CEO di Argan, Inc. (AGX), ha comunicato l’esercizio di un’opzione e la successiva vendita sul mercato aperto il 09/18/2025. Ha esercitato 7.500 azioni di un’opzione concessa il 09/12/2018 a un prezzo di esercizio di $43.10 per azione e ha venduto immediatamente 7.500 azioni sul mercato a $257.39 per azione. Dopo queste operazioni, la nota indica che detiene direttamente 21,006 azioni come beneficiario e 44,735 azioni coperte da opzioni/derivati riportate come possedute come beneficiario. Il modulo Form 4 è stato firmato e datato 09/22/2025.

Charles E. Collins IV, director ejecutivo de Argan, Inc. (AGX), informó el ejercicio de una opción y la venta subsiguiente en el mercado abierto el 09/18/2025. Ejerció 7,500 acciones de una opción concedida el 09/12/2018 a un precio de ejercicio de $43.10 por acción, y vendió inmediatamente 7,500 acciones en el mercado a $257.39 por acción. Tras estas operaciones, el informe indica que posee de forma beneficiosa directamente 21,006 acciones y 44,735 acciones subyacentes a opciones/derivados reportados como poseídas beneficiosamente. El Formulario 4 está firmado y fechado el 09/22/2025.

Charles E. Collins IV, Argan, Inc. (AGX)의 CEO는 2025년 9월 18일 옵션 행사 및 이후 공개 시장 매도를 보고했습니다. 그는 2018년 9월 12일에 부여된 주식 옵션의 행사 가격이 주당 $43.10인 7,500주를 행사했고 즉시 주당 $257.39로 공개 시장에서 7,500주를 매도했습니다. 이 거래 후 해당 보고서에 따르면 직접 유익하게 소유하는 주식은 21,006주, 유익하게 소유로 보고된 옵션/파생상품의 기초 주식 수는 44,735주로 나타납니다. Form 4는 2025년 9월 22일에 서명 및 날짜가 기재되어 있습니다.

Charles E. Collins IV, PDG d’Argan, Inc. (AGX), a annoncé l’exercice d’une option puis une vente sur le marché libre le 18/09/2025. Il a exercé 7 500 actions d’une option accordée le 12/09/2018 à un prix d’exercice de $43,10 par action, et a immédiatement vendu 7 500 actions sur le marché à $257,39 par action. Suite à ces opérations, le dossier indique qu’il détient directement 21 006 actions bénéficiaires et 44 735 actions sous-jacentes à des options/dérivés signalées comme détenues par bénéficiaire. Le Formulaire 4 est signé et daté du 22/09/2025.

Charles E. Collins IV, CEO von Argan, Inc. (AGX), meldete eine Optionsausübung und anschließenden Handel am offenen Markt am 09/18/2025. Er übte 7.500 Aktien einer am 09/12/2018 gewährten Option zu einem Ausübungspreis von $43.10 pro Aktie aus und verkaufte unmittelbar 7.500 Aktien am offenen Markt zu $257.39 pro Aktie. Nach diesen Transaktionen zeigt das Formular, dass er direkt 21,006 Aktien als Begünstigter besitzt und 44,735 Aktien unter Optionen/Derivaten als begünstigt gemeldet besitzt. Das Form 4 ist unterzeichnet und datiert auf den 09/22/2025.

Charles E. Collins IV، الرئيس التنفيذي لشركة Argan، Inc. (AGX)، أبلغ عن ممارسة خيار وبيع في السوق المفتوحة في 18/09/2025. مارس 7,500 سهماً من خيار أسهم مُمنوح في 12/09/2018 بسعر تنفيذ $43.10 للسهم، وباع على الفور 7,500 سهماً في السوق المفتوحة بسعر $257.39 للسهم. بعد هذه العمليات، يبين الملف أن لديه ملكية مباشرة لـ 21,006 سهماً كمالك مستفيد ووجود 44,735 سهماً كأسهم مغطاة بخيارات/مشتقات مُبلَّغ عنها كملك مستفيد. النموذج 4 مُوقَّع ومؤرّخ في 22/09/2025.

Charles E. Collins IV,Argan, Inc.(AGX)的首席执行官,已于 2025 年 9 月 18 日报告行使期权并随后在公开市场出售。其以行使价 $43.10 美元/股,行使了一份于 2018 年 9 月 12 日授予的股票期权,数量为 7,500 股,并以 $257.39 美元/股的价格立即在公开市场出售 7,500 股。交易完成后,该披露显示直接受益持有 21,006 股,以及被列为受益持有的期权/衍生品所涵盖的基础股票数为 44,735 股。Form 4 已签署并日期为 2025-09-22。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: CEO exercised vested options and sold the exercised shares, realizing a large spread between exercise and sale price.

The filing discloses a routine but material executive transaction: exercise of 7,500 options at $43.10 and an immediate sale at $257.39 on 09/18/2025. This realizes substantial pre-tax proceeds for the CEO and reduces his direct share count by the amount sold to 21,006 shares. The disclosure appears complete and timely under Section 16 reporting rules; there is no indication of insider trading plan reliance within the form text.

TL;DR: Transaction reflects option vest/monetization event consistent with executive compensation being realized.

The exercised option was granted 09/12/2018 and remains exercisable through 09/12/2028; exercising 7,500 shares at $43.10 and selling at $257.39 shows a large intrinsic value capture by management. The remaining derivative holdings reported (total underlying common stock equivalent 44,735) indicate continued option exposure. From a compensation perspective, this is a material monetization but not an unusual one for long-dated grants.

Charles E. Collins IV, CEO di Argan, Inc. (AGX), ha comunicato l’esercizio di un’opzione e la successiva vendita sul mercato aperto il 09/18/2025. Ha esercitato 7.500 azioni di un’opzione concessa il 09/12/2018 a un prezzo di esercizio di $43.10 per azione e ha venduto immediatamente 7.500 azioni sul mercato a $257.39 per azione. Dopo queste operazioni, la nota indica che detiene direttamente 21,006 azioni come beneficiario e 44,735 azioni coperte da opzioni/derivati riportate come possedute come beneficiario. Il modulo Form 4 è stato firmato e datato 09/22/2025.

Charles E. Collins IV, director ejecutivo de Argan, Inc. (AGX), informó el ejercicio de una opción y la venta subsiguiente en el mercado abierto el 09/18/2025. Ejerció 7,500 acciones de una opción concedida el 09/12/2018 a un precio de ejercicio de $43.10 por acción, y vendió inmediatamente 7,500 acciones en el mercado a $257.39 por acción. Tras estas operaciones, el informe indica que posee de forma beneficiosa directamente 21,006 acciones y 44,735 acciones subyacentes a opciones/derivados reportados como poseídas beneficiosamente. El Formulario 4 está firmado y fechado el 09/22/2025.

Charles E. Collins IV, Argan, Inc. (AGX)의 CEO는 2025년 9월 18일 옵션 행사 및 이후 공개 시장 매도를 보고했습니다. 그는 2018년 9월 12일에 부여된 주식 옵션의 행사 가격이 주당 $43.10인 7,500주를 행사했고 즉시 주당 $257.39로 공개 시장에서 7,500주를 매도했습니다. 이 거래 후 해당 보고서에 따르면 직접 유익하게 소유하는 주식은 21,006주, 유익하게 소유로 보고된 옵션/파생상품의 기초 주식 수는 44,735주로 나타납니다. Form 4는 2025년 9월 22일에 서명 및 날짜가 기재되어 있습니다.

Charles E. Collins IV, PDG d’Argan, Inc. (AGX), a annoncé l’exercice d’une option puis une vente sur le marché libre le 18/09/2025. Il a exercé 7 500 actions d’une option accordée le 12/09/2018 à un prix d’exercice de $43,10 par action, et a immédiatement vendu 7 500 actions sur le marché à $257,39 par action. Suite à ces opérations, le dossier indique qu’il détient directement 21 006 actions bénéficiaires et 44 735 actions sous-jacentes à des options/dérivés signalées comme détenues par bénéficiaire. Le Formulaire 4 est signé et daté du 22/09/2025.

Charles E. Collins IV, CEO von Argan, Inc. (AGX), meldete eine Optionsausübung und anschließenden Handel am offenen Markt am 09/18/2025. Er übte 7.500 Aktien einer am 09/12/2018 gewährten Option zu einem Ausübungspreis von $43.10 pro Aktie aus und verkaufte unmittelbar 7.500 Aktien am offenen Markt zu $257.39 pro Aktie. Nach diesen Transaktionen zeigt das Formular, dass er direkt 21,006 Aktien als Begünstigter besitzt und 44,735 Aktien unter Optionen/Derivaten als begünstigt gemeldet besitzt. Das Form 4 ist unterzeichnet und datiert auf den 09/22/2025.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Collins Charles Edwin IV

(Last) (First) (Middle)
C/O ARGAN, INC.
4075 WILSON BLVD, SUITE 440

(Street)
ARLINGTON VA 22203

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARGAN INC [ AGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF EXECUTIVE OFFICER, GEMMA
3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/18/2025 M 7,500(1) A $43.1 28,506 D
Common Stock 09/18/2025 S 7,500(2) D $257.39 21,006 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock $43.1 09/18/2025 M 7,500(1) 09/12/2019 09/12/2028 Common Stock 7,500 $43.1 44,735 D
Explanation of Responses:
1. On September 18, 2025, the Reporting Person exercised a portion of his stock option awarded on September 12, 2018 to purchase 7,500 shares of the Issuer's common stock at a price of $43.10 per share.
2. On September 18, 2025, the Reporting Person sold 7,500 of the Issuer's common stock on the open market at a price of $257.39 per share.
/s/ Charles E. Collins IV 09/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Argan Inc

NYSE:AGX

AGX Rankings

AGX Latest News

AGX Latest SEC Filings

AGX Stock Data

3.60B
13.27M
4.48%
89.2%
5.37%
Engineering & Construction
Construction - Special Trade Contractors
Link
United States
ARLINGTON